Skip to application
All calculators and tools
IV Dilution & Medication Referencev7.4
Back to resultsA-Z list

Epinephrine

Dilution requiredFull monograph review pending

Jump to a section

Historical dilution reference. Verify the preparation against the label for the product in hand.

Original GlobalRPh article: Epinephrine (opens in a new tab)Original source URL: https://globalrph.com/dilution/epinephrine/ Retrieved 2026-11-04

Historical source details

Original publication date: unavailable in the retrieved article.

Source location and file checksums
Original source URL
https://globalrph.com/dilution/epinephrine/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:46:38.313662+00:00
Source location
div.post-content
Packaged content SHA-256
cbc6b045d985158fbe304a2a57b728461287ccedf1b7e09622710df4c6168178
Original response SHA-256
6484c985c0a82de45b50d01c2cec75b438db30340bcc93b886221b85c037cdfa
Source body SHA-256
dd83b4834d7b3dc327660ba669088460bcab33b375cade354f2a7ed3a7bf2986

EPINEPHRINE

The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Usual Diluents

NS, D5W

Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate]

[1 to 5 mg] [250 ml] [Titrate]

Central line required for administration.

Stability / Miscellaneous

EXP: 1 DAY (RT).

Dosing:
Continuous infusion: 1 to 4 mcg/min.
Anaphylaxis (adult): 0.1 to 0.5 SC / IM (1:1000) repeat q10 to 15 minutes prn or give 0.1 to 0.25 mg IV (1:10,000) over 5-10min repeat q5 to 15 minutes as needed or start continuous infusion: 1 to 4 mcg/min.

Cardiac arrest: 0.5 to 1 mg bolus (1:10,000) q5min prn. May give 0.3 mg SC or start continuous infusion (range: 1 to 10 mcg/min).

Calculation of drip rate (ml/hr)
1 mg/250 ml: mcg/min x 15.

--------------------------------------------------------------------------------

Dosing (Adults):
Asystole:
I.V.: 1 mg every 3-5 minutes; if this approach fails, higher doses of epinephrine (up to 0.2 mg/kg) may be used, but are not recommended (Class Indeterminate; 2000 ACLS guidelines)

Intratracheal: Administer 2-2.5 times the recommended I.V. dose; dilute in 10 mL NS or distilled water. Note: Absorption is greater with distilled water, but causes more adverse effects on PaO2.

Bronchodilator: I.M., SubQ ( 1:1000 ): 0.1-0.5 mg every 10-15 minutes to 4 hours

Hypersensitivity reaction: I.M., SubQ: 0.3-0.5 mg every 15-20 minutes if condition requires; if hypotension is present: 0.1 mg I.V. slowly over 5-10 minutes followed by continuous infusion 1-10 mcg/minute

Symptomatic bradycardia or heart block (not responsive to atropine or pacing): I.V. infusion: 1-10 mcg/minute; titrate to desired effect

Refractory hypotension (refractory to dopamine/dobutamine): Continuous I.V. infusion 1 mcg/minute (range: 1-10 mcg/minute); titrate dosage to desired effect; severe cardiac dysfunction may require doses >10 mcg/minute (up to 0.1 mcg/kg/minute)

Nebulization: Instill 8-15 drops into nebulizer reservoirs; administer 1-3 inhalations 4-6 times/day

Administration
Central line administration only; intravenous infusions require an infusion pump

Epinephrine can be administered SubQ, I.M., I.V., or intracardiac injection

I.M. administration into the buttocks should be avoided

Preparation of adult I.V. infusion: Dilute 1 mg in 250 mL of D5W or NS (4 mcg/mL); administer at an initial rate of 1 mcg/minute and increase to desired effects; at 20 mcg/minute pure alpha effects occur

Extravasation management: Use phentolamine as antidote. Mix 5 mg with 9 mL of NS. Inject a small amount of this dilution into extravasated area. Blanching should reverse immediately. Monitor site. If blanching should recur, additional injections of phentolamine may be needed.

Stability
Epinephrine is sensitive to light and air; protection from light is recommended.

Oxidation turns drug pink, then a brown color; solutions should not be used if they are discolored or contain a precipitate.

Stability of injection of parenteral admixture at room temperature (25°C) or refrigeration (4°C): 24 hours.

Standard diluent: 1 mg/250 mL NS.

Source: [package insert]

Open this historical article on its own

U.S. label preparation

Epinephrine 1 mg/mL vial · Dilution required

Preparation
For the adult septic-shock IV infusion in this label, dilute 1 mg in 1,000 mL of 5% dextrose or a sodium chloride solution containing 5% dextrose. The labeled concentration is 1 mcg/mL.
Administration and handling
Titrate the infusion to the prescribed blood pressure goal. Use the separate route-specific directions for anaphylaxis.
Product and source details

Amneal Pharmaceuticals LLC · ANDA217485

Product NDC: 70121-1660

SPL effective 2025-10-31 | SPL version 5. Checked 2026-11-13.

Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.

Safety resources for this medication (1)

Read the linked communication and current prescribing information before use. Resource dates and affected product scopes differ; a listed resource is not a full monograph or a lot-specific clearance.

Product identifiers and clinical review status

U.S. label preparation available. Full monograph review pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Obtain independent corroboration of the label preparation where available.
  • Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
  • Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.